SRTA

INSIDER SELL

Strata Critical Medical, Inc.

Research: Finviz ↗·Perplexity ↗

No convergence signal this quarter — shown because tracked funds have filed 13D/G on this stock.

Days to cover (short int.)

6.1d↓-0.6%

as of 2026-09-30

News Summary

Neutral

Strata Critical Medical delivered a strong Q2 2026 revenue beat (+8.2% vs. consensus) with 60.7% YoY growth and raised full-year guidance significantly, but reported a net loss and continued unprofitability despite aggressive M&A expansion. Activist investor Third Point (5.8% stake, Daniel Loeb) announced mid-October push for a strategic sale, signaling potential governance friction and questioning management's standalone strategy.

Red flags

•Continued net losses despite 60.7% revenue growth (Q2 2026: $(10.5)M loss, 14.5% of revenue) signals profitability challenges
•EPS miss despite revenue beat points to deteriorating unit economics or margin pressure
•Co-CEO structure (Heyburn & Tomkiel both CEO since mid-2025) creates governance ambiguity; CNN flagged 'insider shake-up' in August 2026
•Activist Third Point push for sale (Oct 16, 2026) suggests investor skepticism of current management strategy and potential distraction/uncertainty
•Heavy reliance on M&A for growth (three acquisitions in Q2 2026 alone) without demonstrated organic profitability raises integration and sustainability risks

Insider Activity

Name	Title	Type	Shares	Price	Value	Filed	Src
Love Reginald	—	SELL	5K	$5.75	$0.03M	2026-08-10	↗

Fund 13D/13G Filings (1)

Tracked funds' beneficial-ownership filings on this stock — disclosed within days of a position change, fresher than the quarterly 13F. Since Filing compares the stock to SPY from the filing date (shown for filings within the last 90 days).

Fund	Form	∆ Shares	% of Class	Since Filing	Filed	Src
Third Point	SC 13D	NEW	5.8%	+8.4% vs SPY +8.1% abs	2026-10-15	↗